Global Follicle-Stimulating Hormone (FSH) Market By Type (Recombinant FSH, Urinary FSH); By Gender (Male, Female); By Application (Infertility Treatment, Follicle Stimulation, Hypogonadism); By Route of Administration (Subcutaneous Injection (Injected Under the Skin), Intramuscular Injection (Injected into a Muscle)); By End Users (Hospitals, Clinics, Fertility Centers, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global follicle-stimulating hormone (FSH) market is growing at an estimated CAGR of 26% over the forecast period. The amount of development seen by medical science is truly massive. global follicle-stimulating hormone (FSH) market Follicle-stimulating hormone (FSH) is a hormone which is secreted by the anterior pituitary gland. This hormone helps in creation of sperm or ova. Technically, this hormone happens to be a gonadotropin, which is glycoprotein polypeptide based and processed and secreted from gonadotropic cells. Follicle-stimulating hormone (FSH) majorly plays a role in regulating the development, maturation in the period of puberty, processes related to reproduction and growth of human body. Deteriorating quality of food and unhealthy lifestyle is taking toll on people’s health, creating more issues related to fertility and this is the reason why the global follicle-stimulating hormone (FSH) market is growing rapidly.
The demand for treatments involving follicle-stimulating hormone (FSH) slumped in the times of coronavirus pandemic. This impacted the growth of the global follicle-stimulating hormone (FSH) market. Though the market is forecasted to pick up the growth over the period of next few years and witness demand more than pre-pandemic levels.
Type Outlook
On the basis of type, the global follicle-stimulating hormone (FSH) market has been divided into recombinant FSH and urinary FSH. The recombinant FSH comprises of less-acidic isoforms that too in very high levels. On the other hand, urinary FSH has very high percentage of acidic isoforms. Lesser-acidic isoforms that are found in recombinant FSH possess a faster clearance.
Global Follicle-Stimulating Hormone (FSH) Market Revenue & Forecast, (US$ Million), 2022 – 2030
Gender Outlook
On the basis of gender, the global follicle-stimulating hormone (FSH) market has been segmented into male and female. In females, the FSH helps in nourishing and recruiting ovarian follicles in the ovary that are immature. This hormone proves helpful in women who are nearing menopause and intend to have a child. On the other hand, those males who are experiencing low sperm count are finding solace in follicle-stimulating hormone (FSH).
Application Outlook
The application segment of the global follicle-stimulating hormone (FSH) market has been categorised into infertility treatment, follicle stimulation, and hypogonadism. The infertility treatment segment accounts for maximum amount of revenue generated by this market. Poor quality of life, consumption on junk food and rising levels of pollution are affecting fertility of both men and women.
Route of Administration Outlook
The routine of administration segment of the global follicle-stimulating hormone (FSH) market has been divided into subcutaneous injection (injected under the skin) and intramuscular injection (injected into a muscle). While the subcutaneous injection is effective in injecting FSH, the intramuscular injection proves utterly helpful as it acts quickly.
End Users Outlook
The end users’ segment of the global follicle-stimulating hormone (FSH) market has been bifurcated into hospitals, clinics, fertility centers and others. The fertility centers account for maximum amount of revenue made by this market. These centers provide specialized services and this is the reason behind the success of fertility centers.
Region Outlook
On the basis of region, the global follicle-stimulating hormone (FSH) market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America makes most amount of money for this market. Consumption of inorganic food products, and inclination towards drug abuse and has caused several health issues in youngsters.
Competitive Landscape
The report provides both, qualitative and quantitative research of global follicle-stimulating hormone (FSH) market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global follicle-stimulating hormone (FSH) market are listed below:
- Merck KGaA
- Ferring B.V.
- Livzon
- Health Biotech Limited
- Walter Bushnell
- Vhb Life Sciences Limited
- Other Market Participants
Global Follicle-Stimulating Hormone (FSH) Market
By Type
- Recombinant FSH
- Urinary FSH
By Gender
- Male
- Female
By Application
- Infertility Treatment
- Follicle Stimulation
- Hypogonadism
By Route of Administration
- Subcutaneous Injection (Injection Under the Skin)
- Intramuscular Injection (Injected into a Muscle)
By End User
- Hospitals
- Clinics
- Fertility Centers
- Others
By Region
- North America
- S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1.
Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2.
Secondary Research
3.2.1.
Paid Databases
3.2.2. Secondary
Sources
3.3.
Market Size Estimates
3.3.1. Top-Down Approach
3.3.2.
Bottom-Up Approach
3.4.
Data Triangulation Methodology
3.5.
Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Follicle-stimulating Hormone
(FSH) Market
6. Market Synopsis: Follicle-stimulating Hormone (FSH) Market
7. Follicle-stimulating Hormone (FSH) Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1.
Product Definition
7.1.2. Industry Development
7.2.
Market Dynamics
7.2.1. Drivers
7.2.2.
Restraints
7.2.3. Opportunities
7.3. Trends in Follicle-stimulating Hormone
(FSH) Market
7.4.
Market Determinants Radar Chart
7.5.
Macro-Economic and Micro-Economic Indicators: Follicle-stimulating Hormone
(FSH) Market
7.6.
Porter’s Five Force Analysis
7.7. Analysis on Impact of Covid-19 on Global Follicle-stimulating Hormone
(FSH) Market
8. Global Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1.
Global Follicle-stimulating Hormone
(FSH) Market Revenue
(US$ Mn)
8.2.
Global Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Recombinant
FSH
8.2.1.1. Definition
8.2.1.2.
Market Estimation and Penetration, 2015 – 2021
8.2.1.3.
Market Forecast, 2022 – 2030
8.2.1.4.
Compound Annual Growth Rate (CAGR)
8.2.1.5.
Regional Bifurcation
8.2.1.5.1.
North America
8.2.1.5.1.1.
Market Estimation, 2015 – 2021
8.2.1.5.1.2.
Market Forecast, 2022 – 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1.
Market Estimation, 2015 – 2021
8.2.1.5.2.2.
Market Forecast, 2022 – 2030
8.2.1.5.3.
Asia Pacific
8.2.1.5.3.1.
Market Estimation, 2015 – 2021
8.2.1.5.3.2.
Market Forecast, 2022 – 2030
8.2.1.5.4.
Middle East and Africa
8.2.1.5.4.1.
Market Estimation, 2015 – 2021
8.2.1.5.4.2.
Market Forecast, 2022 – 2030
8.2.1.5.5.
Latin America
8.2.1.5.5.1.
Market Estimation, 2015 – 2021
8.2.1.5.5.2.
Market Forecast, 2022 – 2030
8.2.2. Urinary FSH
8.2.2.1.
Definition
8.2.2.2.
Market Estimation and Penetration,
2015 – 2021
8.2.2.3.
Market Forecast, 2022 – 2030
8.2.2.4.
Compound Annual Growth Rate (CAGR)
8.2.2.5.
Regional Bifurcation
8.2.2.5.1.
North America
8.2.2.5.1.1.
Market Estimation, 2015 – 2021
8.2.2.5.1.2.
Market Forecast, 2022 – 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1.
Market Estimation, 2015 – 2021
8.2.2.5.2.2.
Market Forecast, 2022 – 2030
8.2.2.5.3.
Asia Pacific
8.2.2.5.3.1.
Market Estimation, 2015 – 2021
8.2.2.5.3.2.
Market Forecast, 2022 – 2030
8.2.2.5.4.
Middle East and Africa
8.2.2.5.4.1.
Market Estimation, 2015 – 2021
8.2.2.5.4.2.
Market Forecast, 2022 – 2030
8.2.2.5.5.
Latin America
8.2.2.5.5.1.
Market Estimation, 2015 – 2021
8.2.2.5.5.2.
Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1.
By Type
9. Global Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2.
Global Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
9.2.1.
Male
9.2.1.1.
Definition
9.2.1.2.
Market Estimation and Penetration,
2015 – 2021
9.2.1.3.
Market Forecast, 2022 – 2030
9.2.1.4.
Compound Annual Growth Rate (CAGR)
9.2.1.5.
Regional Bifurcation
9.2.1.5.1.
North America
9.2.1.5.1.1.
Market Estimation, 2015 – 2021
9.2.1.5.1.2.
Market Forecast, 2022 – 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1.
Market Estimation, 2015 – 2021
9.2.1.5.2.2.
Market Forecast, 2022 – 2030
9.2.1.5.3.
Asia Pacific
9.2.1.5.3.1.
Market Estimation, 2015 – 2021
9.2.1.5.3.2.
Market Forecast, 2022 – 2030
9.2.1.5.4.
Middle East and Africa
9.2.1.5.4.1.
Market Estimation, 2015 – 2021
9.2.1.5.4.2.
Market Forecast, 2022 – 2030
9.2.1.5.5.
Latin America
9.2.1.5.5.1.
Market Estimation, 2015 – 2021
9.2.1.5.5.2.
Market Forecast, 2022 – 2030
9.2.2. Female
9.2.2.1.
Definition
9.2.2.2.
Market Estimation and Penetration,
2015 – 2021
9.2.2.3.
Market Forecast, 2022 – 2030
9.2.2.4.
Compound Annual Growth Rate (CAGR)
9.2.2.5.
Regional Bifurcation
9.2.2.5.1.
North America
9.2.2.5.1.1.
Market Estimation, 2015 – 2021
9.2.2.5.1.2.
Market Forecast, 2022 – 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1.
Market Estimation, 2015 – 2021
9.2.2.5.2.2.
Market Forecast, 2022 – 2030
9.2.2.5.3.
Asia Pacific
9.2.2.5.3.1.
Market Estimation, 2015 – 2021
9.2.2.5.3.2.
Market Forecast, 2022 – 2030
9.2.2.5.4.
Middle East and Africa
9.2.2.5.4.1.
Market Estimation, 2015 – 2021
9.2.2.5.4.2.
Market Forecast, 2022 – 2030
9.2.2.5.5.
Latin America
9.2.2.5.5.1.
Market Estimation, 2015 – 2021
9.2.2.5.5.2.
Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1.
By Gender
10. Global Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 – 2030
10.1.
Overview
10.2.
Global Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
10.2.1.
Infertility Treatment
10.2.1.1.
Definition
10.2.1.2.
Market Estimation and Penetration,
2015 – 2021
10.2.1.3.
Market Forecast, 2022 – 2030
10.2.1.4.
Compound Annual Growth Rate (CAGR)
10.2.1.5.
Regional Bifurcation
10.2.1.5.1.
North America
10.2.1.5.1.1.
Market Estimation, 2015 – 2021
10.2.1.5.1.2.
Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1.
Market Estimation, 2015 – 2021
10.2.1.5.2.2.
Market Forecast, 2022 – 2030
10.2.1.5.3.
Asia Pacific
10.2.1.5.3.1.
Market Estimation, 2015 – 2021
10.2.1.5.3.2.
Market Forecast, 2022 – 2030 10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 – 2021
10.2.1.5.4.2.
Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1.
Market Estimation, 2015 –
2021
10.2.1.5.5.2.
Market Forecast, 2022 – 2030
10.2.2. Follicle Stimulation
10.2.2.1. Definition
10.2.2.2.
Market Estimation and Penetration,
2015 – 2021
10.2.2.3.
Market Forecast, 2022 – 2030
10.2.2.4.
Compound Annual Growth Rate (CAGR)
10.2.2.5.
Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1.
Market Estimation, 2015 – 2021
10.2.2.5.1.2.
Market Forecast, 2022 – 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1.
Market Estimation, 2015 – 2021
10.2.2.5.2.2.
Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1.
Market Estimation, 2015 – 2021
10.2.2.5.3.2.
Market Forecast, 2022 – 2030 10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5.
Latin America
10.2.2.5.5.1.
Market Estimation, 2015 – 2021
10.2.2.5.5.2.
Market Forecast, 2022 – 2030
10.2.3.
Hypogonadism
10.2.3.1.
Definition
10.2.3.2.
Market Estimation and Penetration,
2015 – 2021
10.2.3.3.
Market Forecast, 2022 – 2030
10.2.3.4.
Compound Annual Growth Rate (CAGR)
10.2.3.5.
Regional Bifurcation
10.2.3.5.1.
North America
10.2.3.5.1.1.
Market Estimation, 2015 – 2021
10.2.3.5.1.2.
Market Forecast, 2022 – 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1.
Market Estimation, 2015 – 2021
10.2.3.5.2.2.
Market Forecast, 2022 – 2030
10.2.3.5.3.
Asia Pacific
10.2.3.5.3.1.
Market Estimation, 2015 – 2021
10.2.3.5.3.2.
Market Forecast, 2022 – 2030 10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1.
Market Estimation, 2015 – 2021
10.2.3.5.4.2.
Market Forecast, 2022 – 2030
10.2.3.5.5.
Latin America
10.2.3.5.5.1.
Market Estimation, 2015 – 2021
10.2.3.5.5.2.
Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1.
By Application
11. Global Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 – 2030
11.1.
Overview
11.2.
Global Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route
of Administration
11.2.1.
Subcutaneous Injection (Injected Under the Skin)
11.2.1.1.
Definition
11.2.1.2.
Market Estimation and Penetration,
2015 – 2021
11.2.1.3.
Market Forecast, 2022 – 2030
11.2.1.4.
Compound Annual Growth
Rate (CAGR)
11.2.1.5.
Regional Bifurcation
11.2.1.5.1.
North America
11.2.1.5.1.1.
Market Estimation, 2015 – 2021
11.2.1.5.1.2.
Market Forecast, 2022 – 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1.
Market Estimation, 2015 – 2021
11.2.1.5.2.2.
Market Forecast, 2022 – 2030
11.2.1.5.3.
Asia Pacific
11.2.1.5.3.1.
Market Estimation, 2015 – 2021
11.2.1.5.3.2.
Market Forecast, 2022 – 2030 11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1.
Market Estimation, 2015 – 2021
11.2.1.5.4.2.
Market Forecast, 2022 – 2030
11.2.1.5.5.
Latin America
11.2.1.5.5.1. Market Estimation, 2015 – 2021
11.2.1.5.5.2.
Market Forecast, 2022 – 2030
11.2.2. Intramuscular Injection (Injected into a Muscle)
11.2.2.1.
Definition
11.2.2.2.
Market Estimation and Penetration,
2015 – 2021
11.2.2.3.
Market Forecast, 2022 – 2030
11.2.2.4.
Compound Annual Growth Rate (CAGR)
11.2.2.5.
Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1.
Market Estimation, 2015 – 2021
11.2.2.5.1.2.
Market Forecast, 2022 – 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1.
Market Estimation, 2015 – 2021
11.2.2.5.2.2.
Market Forecast, 2022 – 2030
11.2.2.5.3.
Asia Pacific
11.2.2.5.3.1.
Market Estimation, 2015 – 2021
11.2.2.5.3.2.
Market Forecast, 2022 – 2030 11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 – 2021
11.2.2.5.4.2.
Market Forecast, 2022 – 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1.
Market Estimation, 2015 – 2021
11.2.2.5.5.2.
Market Forecast, 2022 – 2030
11.3. Key Segment for Channeling Investments
11.3.1.
By Route of Administration
12. Global Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 – 2030
12.1.
Overview
12.2.
Global Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End
Users
12.2.1.
Hospitals
12.2.1.1.
Definition
12.2.1.2.
Market Estimation and Penetration,
2015 – 2021
12.2.1.3.
Market Forecast, 2022 – 2030
12.2.1.4.
Compound Annual Growth Rate (CAGR)
12.2.1.5.
Regional Bifurcation
12.2.1.5.1.
North America
12.2.1.5.1.1.
Market Estimation, 2015 – 2021
12.2.1.5.1.2.
Market Forecast, 2022 – 2030
12.2.1.5.2. Europe
12.2.1.5.2.1.
Market Estimation, 2015 – 2021
12.2.1.5.2.2.
Market Forecast, 2022 – 2030
12.2.1.5.3.
Asia Pacific
12.2.1.5.3.1.
Market Estimation, 2015 – 2021
12.2.1.5.3.2.
Market Forecast, 2022 – 2030 12.2.1.5.4. Middle East and Africa
12.2.2.
Clinics
12.2.1.5.4.1.
Market Estimation, 2015 – 2021
12.2.1.5.4.2.
Market Forecast, 2022 – 2030
12.2.1.5.5. Latin America
12.2.1.5.5.1.
Market Estimation, 2015 – 2021
12.2.1.5.5.2.
Market Forecast, 2022 – 2030
12.2.2.1.
Definition
12.2.2.2.
Market Estimation and Penetration,
2015 – 2021
12.2.2.3.
Market Forecast, 2022 – 2030
12.2.2.4.
Compound Annual Growth Rate (CAGR)
12.2.2.5.
Regional Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1.
Market Estimation, 2015 – 2021
12.2.2.5.1.2.
Market Forecast, 2022 – 2030
12.2.2.5.2.
Europe
12.2.2.5.2.1.
Market Estimation, 2015 – 2021
12.2.2.5.2.2.
Market Forecast, 2022 – 2030
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1.
Market Estimation, 2015 – 2021
12.2.2.5.3.2.
Market Forecast, 2022 – 2030 12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market Estimation, 2015 – 2021
12.2.2.5.4.2. Market Forecast, 2022 – 2030
12.2.2.5.5.
Latin America
12.2.2.5.5.1.
Market Estimation, 2015 – 2021
12.2.2.5.5.2.
Market Forecast, 2022 – 2030
12.2.3.
Fertility Centers
12.2.3.1.
Definition
12.2.3.2.
Market Estimation and Penetration,
2015 – 2021
12.2.3.3.
Market Forecast, 2022 – 2030
12.2.3.4.
Compound Annual Growth Rate (CAGR)
12.2.3.5.
Regional Bifurcation
12.2.3.5.1. North America
12.2.3.5.1.1.
Market Estimation, 2015 – 2021
12.2.3.5.1.2.
Market Forecast, 2022 – 2030
12.2.3.5.2.
Europe
12.2.3.5.2.1.
Market Estimation, 2015 – 2021
12.2.3.5.2.2.
Market Forecast, 2022 – 2030
12.2.3.5.3.
Asia Pacific
12.2.3.5.3.1.
Market Estimation, 2015 – 2021
12.2.3.5.3.2.
Market Forecast, 2022 – 2030 12.2.3.5.4. Middle East and Africa
12.2.3.5.4.1. Market Estimation, 2015 – 2021
12.2.3.5.4.2.
Market Forecast, 2022 – 2030
12.2.3.5.5.
Latin America
12.2.3.5.5.1.
Market Estimation, 2015 – 2021
12.2.3.5.5.2.
Market Forecast, 2022 – 2030
12.2.4.
Others
12.2.4.1.
Definition
12.2.4.2.
Market Estimation and Penetration,
2015 – 2021
12.2.4.3.
Market Forecast, 2022 – 2030
12.2.4.4.
Compound Annual Growth Rate (CAGR)
12.2.4.5.
Regional Bifurcation
12.2.4.5.1. North America
12.2.4.5.1.1.
Market Estimation, 2015 – 2021
12.2.4.5.1.2.
Market Forecast, 2022 – 2030
12.2.4.5.2.
Europe
12.2.4.5.2.1.
Market Estimation, 2015 – 2021
12.2.4.5.2.2.
Market Forecast, 2022 – 2030
12.2.4.5.3.
Asia Pacific
12.2.4.5.3.1.
Market Estimation, 2015 – 2021
12.2.4.5.3.2.
Market Forecast, 2022 – 2030 12.2.4.5.4. Middle East and Africa
12.2.4.5.4.1. Market Estimation, 2015 – 2021
12.2.4.5.4.2.
Market Forecast, 2022 – 2030
12.2.4.5.5.
Latin America
12.2.4.5.5.1.
Market Estimation, 2015 – 2021
12.2.4.5.5.2. Market Forecast, 2022 – 2030
12.3. Key Segment for Channeling Investments
12.3.1.
By End Users
13. North America Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 - 2030
13.1.
Overview
13.1.1. North America Follicle-stimulating Hormone
(FSH) Market Revenue
(US$ Mn)
13.2.
North America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1.
Recombinant FSH
13.2.2. Urinary FSH
13.3.
North America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Gender
13.3.1.
Male
13.3.2.
Female
13.4.
North America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1.
Infertility Treatment
13.4.2. Follicle Stimulation
13.4.3. Hypogonadism
13.5.
North America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.5.1.
Subcutaneous Injection (Injected Under the Skin)
13.5.2.
Intramuscular Injection
(Injected into a Muscle)
13.6.
North America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By End Users
13.6.1.
Hospitals
13.6.2. Clinics
13.6.3. Fertility
Centers
13.6.4. Others
13.7.
North America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1.
U.S
13.7.1.1.
U.S Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Type
13.7.1.1.1. Recombinant FSH
13.7.1.1.2. Urinary FSH
13.7.1.2.
U.S Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Gender
13.7.1.2.1. Male
13.7.1.2.2. Female
13.7.1.3.
U.S Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Application
13.7.1.3.1. Infertility Treatment
13.7.1.3.2.
Follicle Stimulation
13.7.1.3.3. Hypogonadism
13.7.1.4.
U.S Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
13.7.1.4.1.
Subcutaneous Injection (Injected Under the Skin) 13.7.1.4.2. Intramuscular Injection (Injected into a Muscle)
13.7.1.5.
U.S Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By End Users
13.7.2.
Canada
13.7.1.5.1. Hospitals
13.7.1.5.2.
Clinics
13.7.1.5.3. Fertility Centers
13.7.1.5.4.
Others
13.7.2.1.
Canada Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
13.7.2.1.1. Recombinant FSH
13.7.2.1.2.
Urinary FSH
13.7.2.2.
Canada Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
13.7.2.2.1. Male
13.7.2.2.2. Female
13.7.2.3.
Canada Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.2.3.1. Infertility Treatment
13.7.2.3.2.
Follicle Stimulation
13.7.2.3.3. Hypogonadism
13.7.2.4.
Canada Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route
of Administration
13.7.2.4.1.
Subcutaneous Injection (Injected Under the Skin) 13.7.2.4.2. Intramuscular Injection (Injected into a Muscle)
13.7.2.5.
Canada Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
13.7.2.5.1. Hospitals
13.7.2.5.2.
Clinics
13.7.2.5.3. Fertility Centers
13.7.2.5.4.
Others
13.7.3. Mexico
13.7.3.1.
Mexico Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
13.7.3.1.1. Recombinant FSH
13.7.3.1.2.
Urinary FSH
13.7.3.2.
Mexico Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
13.7.3.2.1. Male
13.7.3.2.2.
Female
13.7.3.3.
Mexico Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
13.7.3.3.1. Infertility Treatment
13.7.3.3.2.
Follicle Stimulation
13.7.3.3.3. Hypogonadism
13.7.3.4.
Mexico Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.3.4.1.
Subcutaneous Injection (Injected Under the Skin) 13.7.3.4.2. Intramuscular Injection (Injected into a Muscle)
13.7.3.5.
Mexico Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
13.7.3.5.1. Hospitals
13.7.3.5.2.
Clinics
13.7.3.5.3.
Fertility Centers
13.7.3.5.4. Others
13.7.4. Rest of
North America
13.7.4.1.
Rest of North America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Type
13.7.4.1.1. Recombinant FSH
13.7.4.1.2.
Urinary FSH
13.7.4.2.
Rest of North America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Gender
13.7.4.2.1. Male
13.7.4.2.2.
Female
13.7.4.3.
Rest of North America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Application
13.7.4.3.1. Infertility Treatment
13.7.4.3.2. Follicle Stimulation
13.7.4.3.3.
Hypogonadism
13.7.4.4.
Rest of North America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.7.4.4.1.
Subcutaneous Injection (Injected Under the Skin) 13.7.4.4.2. Intramuscular Injection (Injected into a Muscle)
13.7.4.5.
Rest of North America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By End Users
13.7.4.5.1. Hospitals
13.7.4.5.2. Clinics
13.7.4.5.3.
Fertility Centers
13.7.4.5.4. Others
13.8.
Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Type
13.8.3.
By Gender
13.8.4. By Application
13.8.5.
By Route of Administration
13.8.6. By End Users
14. Europe Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 - 2030
14.1.
Overview
14.1.1. Europe Follicle-stimulating Hormone
(FSH) Market Revenue
(US$ Mn)
14.2.
Europe Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
14.2.1.
Recombinant FSH
14.2.2. Urinary FSH
14.3.
Europe Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
14.3.1.
Male
14.3.2.
Female
14.4.
Europe Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
14.4.1.
Infertility Treatment
14.4.2. Follicle Stimulation
14.4.3.
Hypogonadism
14.5.
Europe Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route
of Administration
14.5.1.
Subcutaneous Injection (Injected Under the Skin)
14.5.2.
Intramuscular Injection
(Injected into a Muscle)
14.6.
Europe Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End
Users
14.6.1.
Hospitals
14.6.2. Clinics
14.6.3. Fertility Centers
14.6.4. Others
14.7.
Europe Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Country
14.7.1.
France
14.7.1.1.
France Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
14.7.1.1.1. Recombinant FSH
14.7.1.1.2. Urinary FSH
14.7.1.2.
France Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
14.7.1.2.1. Male
14.7.1.2.2.
Female
14.7.1.3.
France Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.1.3.1. Infertility Treatment
14.7.1.3.2.
Follicle Stimulation
14.7.1.3.3. Hypogonadism
14.7.1.4.
France Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.1.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.1.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.1.5.
France Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.7.1.5.1. Hospitals
14.7.1.5.2. Clinics
14.7.1.5.3.
Fertility Centers
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1.
The UK Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
14.7.2.1.1. Recombinant FSH
14.7.2.1.2.
Urinary FSH
14.7.2.2.
The UK Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
14.7.2.2.1. Male
14.7.2.2.2.
Female
14.7.2.3.
The UK Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.2.3.1. Infertility Treatment
14.7.2.3.2.
Follicle Stimulation
14.7.2.3.3. Hypogonadism
14.7.2.4.
The UK Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.2.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.2.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.2.5.
The UK Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.7.2.5.1. Hospitals
14.7.2.5.2. Clinics
14.7.2.5.3.
Fertility Centers
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1.
Spain Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
14.7.3.1.1. Recombinant FSH
14.7.3.1.2. Urinary FSH
14.7.3.2.
Spain Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
14.7.3.2.1. Male
14.7.3.2.2. Female
14.7.3.3.
Spain Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.3.3.1. Infertility Treatment
14.7.3.3.2. Follicle Stimulation
14.7.3.3.3.
Hypogonadism
14.7.3.4.
Spain Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.3.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.3.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.3.5.
Spain Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.7.3.5.1. Hospitals
14.7.3.5.2.
Clinics
14.7.3.5.3. Fertility Centers
14.7.3.5.4.
Others
14.7.4. Germany
14.7.4.1.
Germany Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
14.7.4.1.1. Recombinant FSH
14.7.4.1.2.
Urinary FSH
14.7.4.2.
Germany Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
14.7.4.2.1. Male
14.7.4.2.2.
Female
14.7.4.3.
Germany Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.4.3.1. Infertility Treatment
14.7.4.3.2.
Follicle Stimulation
14.7.4.3.3.
Hypogonadism
14.7.4.4.
Germany Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.4.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.4.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.4.5.
Germany Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.7.4.5.1. Hospitals
14.7.5.
Italy
14.7.5.1.1. Clinics
14.7.5.1.2. Fertility Centers
14.7.5.1.3. Others
14.7.5.2.
Italy Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
14.7.5.2.1. Recombinant FSH
14.7.5.2.2.
Urinary FSH
14.7.5.3.
Italy Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
14.7.5.3.1. Male
14.7.5.3.2.
Female
14.7.5.4.
Italy Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
14.7.5.4.1. Infertility Treatment
14.7.5.4.2.
Follicle Stimulation
14.7.5.4.3.
Hypogonadism
14.7.5.5.
Italy Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.5.5.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.5.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.5.6.
Italy Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
14.7.5.6.1. Hospitals
14.7.5.6.2.
Clinics
14.7.5.6.3.
Fertility Centers
14.7.5.6.4.
Others
14.7.6. Nordic Countries
14.7.6.1.
Nordic Countries Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Type
14.7.6.1.1. Recombinant FSH
14.7.6.1.2. Urinary FSH
14.7.6.2.
Nordic Countries Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Gender
14.7.6.2.1. Male
14.7.6.2.2.
Female
14.7.6.3.
Nordic Countries Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Application
14.7.6.3.1. Infertility Treatment
14.7.6.3.2. Follicle Stimulation
14.7.6.3.3.
Hypogonadism
14.7.6.4.
Nordic Countries Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.6.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.6.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.6.5.
Nordic Countries Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.6.5.1. Hospitals
14.7.6.5.2.
Clinics
14.7.6.5.3. Fertility Centers
14.7.6.5.4.
Others
14.7.6.6.
Nordic Countries Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3.
Iceland
14.7.6.6.4.
Sweden
14.7.6.6.5.
Norway
14.7.7.
Benelux Union
14.7.7.1.
Benelux Union Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Type
14.7.7.1.1. Recombinant FSH
14.7.7.1.2. Urinary FSH
14.7.7.2.
Benelux Union Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Gender
14.7.7.2.1. Male
14.7.7.2.2.
Female
14.7.7.3.
Benelux Union Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Application
14.7.7.3.1. Infertility Treatment
14.7.7.3.2.
Follicle Stimulation
14.7.7.3.3.
Hypogonadism
14.7.7.4.
Benelux Union Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.7.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.7.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.7.5.
Benelux Union Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.7.5.1. Hospitals
14.7.7.5.2.
Clinics
14.7.7.5.3.
Fertility Centers
14.7.7.5.4.
Others
14.7.7.6.
Benelux Union Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3.
Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of Europe Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Type
14.7.8.1.1. Recombinant FSH
14.7.8.1.2.
Urinary FSH
14.7.8.2.
Rest of Europe Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Gender
14.7.8.2.1. Male
14.7.8.2.2.
Female
14.7.8.3.
Rest of Europe Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Application
14.7.8.3.1. Infertility Treatment
14.7.8.3.2.
Follicle Stimulation
14.7.8.3.3.
Hypogonadism
14.7.8.4.
Rest of Europe Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
14.7.8.4.1.
Subcutaneous Injection (Injected Under the Skin) 14.7.8.4.2. Intramuscular Injection (Injected into a Muscle)
14.7.8.5.
Rest of Europe Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By End Users
14.7.8.5.1. Hospitals
14.7.8.5.2.
Clinics
14.7.8.5.3.
Fertility Centers
14.7.8.5.4.
Others
14.8.
Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Type
14.8.3. By Gender
14.8.4.
By Application
14.8.5. By Route of Administration
14.8.6.
By End Users
15. Asia Pacific Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 - 2030
15.1.
Overview
15.1.1.
Asia Pacific
Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn)
15.2.
Asia Pacific Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.2.1.
Recombinant FSH
15.2.2.
Urinary FSH
15.3.
Asia Pacific Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.3.1.
Male
15.3.2. Female
15.4.
Asia Pacific Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.4.1.
Infertility Treatment
15.4.2. Follicle Stimulation
15.4.3.
Hypogonadism
15.5.
Asia Pacific Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.5.1.
Subcutaneous Injection (Injected Under the Skin)
15.5.2. Intramuscular Injection (Injected into a Muscle)
15.6.
Asia Pacific Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
15.6.1.
Hospitals
15.6.2. Clinics
15.6.3. Fertility Centers
15.6.4.
Others
15.7.
Asia Pacific Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Country
15.7.1.
China
15.7.1.1.
China Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.1.1.1. Recombinant FSH
15.7.1.1.2.
Urinary FSH
15.7.1.2.
China Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.7.1.2.1. Male
15.7.1.2.2.
Female
15.7.1.3.
China Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.1.3.1. Infertility Treatment
15.7.1.3.2.
Follicle Stimulation
15.7.1.3.3.
Hypogonadism
15.7.1.4.
China Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.1.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.1.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.1.5.
China Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By End Users
15.7.1.5.1. Hospitals
15.7.1.5.2.
Clinics
15.7.1.5.3. Fertility Centers
15.7.1.5.4.
Others
15.7.2. Japan
15.7.2.1.
Japan Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.2.1.1. Recombinant FSH
15.7.2.1.2. Urinary FSH
15.7.2.2.
Japan Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.7.2.2.1. Male
15.7.2.2.2.
Female
15.7.2.3.
Japan Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.2.3.1. Infertility Treatment
15.7.2.3.2.
Follicle Stimulation
15.7.2.3.3.
Hypogonadism
15.7.2.4.
Japan Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.2.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.2.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.2.5.
Japan Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.2.5.1. Hospitals
15.7.2.5.2.
Clinics
15.7.2.5.3.
Fertility Centers
15.7.2.5.4. Others
15.7.3. India
15.7.3.1.
India Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.3.1.1. Recombinant FSH
15.7.3.1.2. Urinary FSH
15.7.3.2.
India Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.7.3.2.1. Male
15.7.3.2.2.
Female
15.7.3.3.
India Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.3.3.1. Infertility Treatment
15.7.3.3.2. Follicle Stimulation
15.7.3.3.3.
Hypogonadism
15.7.3.4.
India Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.3.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.3.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.3.5.
India Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.3.5.1. Hospitals
15.7.3.5.2.
Clinics
15.7.3.5.3. Fertility Centers
15.7.3.5.4.
Others
15.7.4. New Zealand
15.7.4.1.
New Zealand Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.4.1.1. Recombinant FSH
15.7.4.1.2.
Urinary FSH
15.7.4.2.
New Zealand Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.7.4.2.1. Male
15.7.4.2.2. Female
15.7.4.3.
New Zealand Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.4.3.1. Infertility Treatment
15.7.4.3.2.
Follicle Stimulation
15.7.4.3.3.
Hypogonadism
15.7.4.4.
New Zealand Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.4.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.4.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.4.5.
New Zealand Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.4.5.1. Hospitals
15.7.4.5.2.
Clinics
15.7.4.5.3. Fertility Centers
15.7.4.5.4.
Others
15.7.5. Australia
15.7.5.1.
Australia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.5.1.1. Recombinant FSH
15.7.5.1.2. Urinary FSH
15.7.5.2.
Australia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.7.5.2.1. Male
15.7.5.2.2.
Female
15.7.5.3.
Australia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.5.3.1. Infertility Treatment
15.7.5.3.2.
Follicle Stimulation
15.7.5.3.3. Hypogonadism
15.7.5.4.
Australia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.5.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.5.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.5.5.
Australia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.5.5.1. Hospitals
15.7.5.5.2.
Clinics
15.7.5.5.3.
Fertility Centers
15.7.5.5.4.
Others
15.7.6.
South Korea
15.7.6.1.
South Korea Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
15.7.6.1.1. Recombinant FSH
15.7.6.1.2.
Urinary FSH
15.7.6.2.
South Korea Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
15.7.6.2.1. Male
15.7.6.2.2.
Female
15.7.6.3.
South Korea Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
15.7.6.3.1. Infertility Treatment
15.7.6.3.2.
Follicle Stimulation
15.7.6.3.3.
Hypogonadism
15.7.6.4.
South Korea Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.6.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.6.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.6.5.
South Korea Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
15.7.6.5.1. Hospitals
15.7.6.5.2. Clinics
15.7.6.5.3.
Fertility Centers
15.7.6.5.4.
Others
15.7.7. Southeast Asia
15.7.7.1.
Southeast Asia Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Type
15.7.7.1.1. Recombinant FSH
15.7.7.1.2.
Urinary FSH
15.7.7.2.
Southeast Asia Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Gender
15.7.7.2.1. Male
15.7.7.2.2. Female
15.7.7.3.
Southeast Asia Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Application
15.7.7.3.1. Infertility Treatment
15.7.7.3.2.
Follicle Stimulation
15.7.7.3.3.
Hypogonadism
15.7.7.4.
Southeast Asia Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.7.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.7.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.7.5.
Southeast Asia Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.7.5.1. Hospitals
15.7.7.5.2. Clinics
15.7.7.5.3.
Fertility Centers
15.7.7.5.4.
Others
15.7.7.6.
Southeast Asia Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.7.6.1. Indonesia
15.7.7.6.2.
Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4.
Singapore
15.7.7.6.5.
Rest of Southeast Asia
15.7.8.
Rest of Asia Pacific
15.7.8.1.
Rest of Asia Pacific Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Type
15.7.8.1.1. Recombinant FSH
15.7.8.1.2. Urinary FSH
15.7.8.2.
Rest of Asia Pacific Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Gender
15.7.8.2.1. Male
15.7.8.2.2. Female
15.7.8.3.
Rest of Asia Pacific Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Application
15.7.8.3.1. Infertility Treatment
15.7.8.3.2. Follicle Stimulation
15.7.8.3.3.
Hypogonadism
15.7.8.4.
Rest of Asia Pacific Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.8.4.1.
Subcutaneous Injection (Injected Under the Skin) 15.7.8.4.2. Intramuscular Injection (Injected into a Muscle)
15.7.8.5.
Rest of Asia Pacific Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By End Users
15.7.8.5.1. Hospitals
15.7.8.5.2.
Clinics
15.7.8.5.3. Fertility Centers
15.7.8.5.4.
Others
15.8.
Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Type
15.8.3.
By Gender
15.8.4. By Application
15.8.5.
By Route of Administration
15.8.6. By End Users
16. Middle East and Africa Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 - 2030
16.1.
Overview
16.1.1. Middle East
and Africa Follicle-stimulating Hormone (FSH) Market Revenue (US$ Mn)
16.2.
Middle East and Africa Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1.
Recombinant FSH
16.2.2. Urinary FSH
16.3.
Middle East and Africa Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Gender
16.3.1.
Male
16.3.2.
Female
16.4.
Middle East and Africa Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Application
16.4.1.
Infertility Treatment
16.4.2.
Follicle Stimulation
16.4.3. Hypogonadism
16.5.
Middle East and Africa Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.5.1.
Subcutaneous Injection (Injected Under the Skin)
16.5.2. Intramuscular Injection (Injected into a Muscle)
16.6.
Middle East and Africa Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By End Users
16.6.1.
Hospitals
16.6.2.
Clinics
16.6.3. Fertility Centers
16.6.4. Others
16.7.
Middle East and Africa Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1.
Saudi Arabia
16.7.1.1.
Saudi Arabia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
16.7.1.1.1. Recombinant FSH
16.7.1.1.2.
Urinary FSH
16.7.1.2.
Saudi Arabia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
16.7.1.2.1. Male
16.7.1.2.2. Female
16.7.1.3.
Saudi Arabia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
16.7.1.3.1. Infertility Treatment
16.7.1.3.2. Follicle Stimulation
16.7.1.3.3.
Hypogonadism
16.7.1.4.
Saudi Arabia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.1.4.1.
Subcutaneous Injection (Injected Under the Skin) 16.7.1.4.2. Intramuscular Injection (Injected into a Muscle)
16.7.1.5.
Saudi Arabia Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
16.7.1.5.1. Hospitals
16.7.1.5.2.
Clinics
16.7.1.5.3. Fertility Centers
16.7.1.5.4.
Others
16.7.2.
UAE
16.7.2.1.
UAE Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Type
16.7.2.1.1. Recombinant FSH
16.7.2.1.2. Urinary FSH
16.7.2.2.
UAE Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Gender
16.7.2.2.1. Male
16.7.2.2.2. Female
16.7.2.3.
UAE Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Application
16.7.2.3.1. Infertility Treatment
16.7.2.3.2.
Follicle Stimulation
16.7.2.3.3. Hypogonadism
16.7.2.4.
UAE Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By Route of Administration
16.7.2.4.1.
Subcutaneous Injection (Injected Under the Skin) 16.7.2.4.2. Intramuscular Injection (Injected into a Muscle)
16.7.2.5.
UAE Follicle-stimulating Hormone (FSH) Market Revenue
(US$ Mn) and Forecasts, By End Users
16.7.2.5.1. Hospitals
16.7.2.5.2. Clinics
16.7.2.5.3.
Fertility Centers
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1.
Egypt Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
16.7.3.1.1. Recombinant FSH
16.7.3.1.2.
Urinary FSH
16.7.3.2.
Egypt Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
16.7.3.2.1. Male
16.7.3.2.2.
Female
16.7.3.3.
Egypt Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
16.7.3.3.1. Infertility Treatment
16.7.3.3.2.
Follicle Stimulation
16.7.3.3.3. Hypogonadism
16.7.3.4.
Egypt Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.3.4.1. Subcutaneous Injection (Injected Under the Skin)
16.7.3.4.2. Intramuscular Injection
(Injected into a Muscle)
16.7.3.5.
Egypt Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
16.7.3.5.1. Hospitals
16.7.3.5.2. Clinics
16.7.3.5.3.
Fertility Centers
16.7.3.5.4.
Others
16.7.4. Kuwait
16.7.4.1.
Kuwait Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
16.7.4.1.1. Recombinant FSH
16.7.4.1.2.
Urinary FSH
16.7.4.2.
Kuwait Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
16.7.4.2.1. Male
16.7.4.2.2.
Female
16.7.4.3.
Kuwait Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
16.7.4.3.1. Infertility Treatment
16.7.4.3.2.
Follicle Stimulation
16.7.4.3.3.
Hypogonadism
16.7.4.4.
Kuwait Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.4.4.1.
Subcutaneous Injection (Injected Under the Skin) 16.7.4.4.2. Intramuscular Injection (Injected into a Muscle)
16.7.4.5.
Kuwait Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
16.7.4.5.1. Hospitals
16.7.4.5.2.
Clinics
16.7.4.5.3.
Fertility Centers
16.7.4.5.4.
Others
16.7.5.
South Africa
16.7.5.1.
South Africa Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
16.7.5.1.1. Recombinant FSH
16.7.5.1.2.
Urinary FSH
16.7.5.2.
South Africa Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
16.7.5.2.1. Male
16.7.5.2.2. Female
16.7.5.3.
South Africa Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
16.7.5.3.1. Infertility Treatment
16.7.5.3.2. Follicle Stimulation
16.7.5.3.3.
Hypogonadism
16.7.5.4.
South Africa Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.5.4.1.
Subcutaneous Injection (Injected Under the Skin) 16.7.5.4.2. Intramuscular Injection (Injected into a Muscle)
16.7.5.5.
South Africa Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
16.7.5.5.1. Hospitals
16.7.5.5.2.
Clinics
16.7.5.5.3. Fertility Centers
16.7.5.5.4.
Others
16.7.6. Rest of Middle
East & Africa
16.7.6.1.
Rest of Middle East & Africa Follicle-stimulating
Hormone (FSH) Market Revenue (US$ Mn) and Forecasts, By Type
16.7.6.1.1. Recombinant FSH
16.7.6.1.2.
Urinary FSH
16.7.6.2.
Rest of Middle East & Africa Follicle-stimulating
Hormone (FSH) Market Revenue (US$ Mn) and Forecasts, By Gender
16.7.6.2.1. Male
16.7.6.2.2. Female
16.7.6.3.
Rest of Middle East & Africa Follicle-stimulating
Hormone (FSH) Market Revenue (US$ Mn) and Forecasts, By Application
16.7.6.3.1. Infertility Treatment
16.7.6.3.2.
Follicle Stimulation
16.7.6.3.3.
Hypogonadism
16.7.6.4.
Rest of Middle East & Africa Follicle-stimulating
Hormone (FSH) Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.7.6.4.1.
Subcutaneous Injection (Injected Under the Skin) 16.7.6.4.2. Intramuscular Injection (Injected into a Muscle)
16.7.6.5.
Rest of Middle East & Africa Follicle-stimulating
Hormone (FSH) Market Revenue (US$ Mn) and Forecasts, By End Users
16.7.6.5.1. Hospitals
16.7.6.5.2.
Clinics
16.7.6.5.3. Fertility Centers
16.7.6.5.4.
Others
16.8.
Key Segment for Channeling Investments
16.8.1. By Country
16.8.2.
By Type
16.8.3. By Gender
16.8.4.
By Application
16.8.5. By Route of Administration
16.8.6. By End Users
17. Latin America Follicle-stimulating Hormone (FSH) Market Analysis and Forecasts, 2022 - 2030
17.1.
Overview
17.1.1. Latin America Follicle-stimulating Hormone
(FSH) Market Revenue
(US$ Mn)
17.2.
Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Type
17.2.1.
Recombinant FSH
17.2.2.
Urinary FSH
17.3.
Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Gender
17.3.1.
Male
17.3.2. Female
17.4.
Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Application
17.4.1.
Infertility Treatment
17.4.2. Follicle Stimulation
17.4.3.
Hypogonadism
17.5.
Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.5.1.
Subcutaneous Injection (Injected Under the Skin)
17.5.2. Intramuscular Injection (Injected into a Muscle)
17.6.
Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By End Users
17.6.1.
Hospitals
17.6.2. Clinics
17.6.3. Fertility Centers
17.6.4. Others
17.7.
Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1.
Brazil
17.7.1.1.
Brazil Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
17.7.1.1.1. Recombinant FSH
17.7.1.1.2.
Urinary FSH
17.7.1.2.
Brazil Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
17.7.1.2.1. Male
17.7.1.2.2.
Female
17.7.1.3.
Brazil Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.1.3.1. Infertility Treatment
17.7.1.3.2.
Follicle Stimulation
17.7.1.3.3.
Hypogonadism
17.7.1.4.
Brazil Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.1.4.1.
Subcutaneous Injection (Injected Under the Skin) 17.7.1.4.2. Intramuscular Injection (Injected into a Muscle)
17.7.1.5.
Brazil Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
17.7.1.5.1. Hospitals
17.7.1.5.2.
Clinics
17.7.1.5.3.
Fertility Centers
17.7.1.5.4.
Others
17.7.2.
Argentina
17.7.2.1.
Argentina Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Type
17.7.2.1.1. Recombinant FSH
17.7.2.1.2. Urinary FSH
17.7.2.2.
Argentina Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Gender
17.7.2.2.1. Male
17.7.2.2.2.
Female
17.7.2.3.
Argentina Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Application
17.7.2.3.1. Infertility Treatment
17.7.2.3.2.
Follicle Stimulation
17.7.2.3.3.
Hypogonadism
17.7.2.4.
Argentina Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
17.7.2.4.1.
Subcutaneous Injection (Injected Under the Skin) 17.7.2.4.2. Intramuscular Injection (Injected into a Muscle)
17.7.2.5.
Argentina Follicle-stimulating Hormone (FSH) Market
Revenue (US$ Mn) and Forecasts, By End Users
17.7.2.5.1. Hospitals
17.7.2.5.2.
Clinics
17.7.2.5.3.
Fertility Centers
17.7.2.5.4.
Others
17.7.3.
Rest of Latin America
17.7.3.1.
Rest of Latin America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Type
17.7.3.1.1. Recombinant FSH
17.7.3.1.2. Urinary FSH
17.7.3.2.
Rest of Latin America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Gender
17.7.3.2.1. Male
17.7.3.2.2. Female
17.7.3.3.
Rest of Latin America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By Application
17.7.3.3.1. Infertility Treatment
17.7.3.3.2.
Follicle Stimulation
17.7.3.3.3. Hypogonadism
17.7.3.4.
Rest of Latin America Follicle-stimulating Hormone (FSH)
Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.3.4.1.
Subcutaneous Injection (Injected Under the Skin) 17.7.3.4.2. Intramuscular Injection (Injected into a Muscle)
17.7.3.5.
Rest of Latin America Follicle-stimulating Hormone
(FSH) Market Revenue (US$ Mn) and Forecasts, By End Users
17.7.3.5.1. Hospitals
17.7.3.5.2. Clinics
17.7.3.5.3.
Fertility Centers
17.7.3.5.4. Others
17.8.
Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Type
17.8.3. By Gender
17.8.4.
By Application
17.8.5. By Route of Administration
17.8.6. By End Users
18. Competitive Benchmarking
18.1.
Market Share Analysis, 2021
18.2.
Global Presence and Growth Strategies
18.2.1.
Mergers and Acquisitions
18.2.2. Product Launches
18.2.3. Investments
Trends
18.2.4. R&D Initiatives
19. Player Profiles
19.1.
Ferring B.V.
19.1.1.
Company Details
19.1.2. Company Overview
19.1.3.
Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7.
Business Strategies
19.2.
Fujirebio
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4.
Key Developments
19.2.5. Financial Analysis
19.2.6.
SWOT Analysis
19.2.7. Business Strategies
19.3.
GeneScience Pharmaceuticals Co., Ltd.
19.3.1. Company Details
19.3.2.
Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7.
Business Strategies
19.4.
Health Biotech Limited
19.4.1.
Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6.
SWOT Analysis
19.4.7. Business Strategies
19.5.
IBSA Institut Biochimique SA
19.5.1.
Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4.
Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6.
Livzon
19.6.1. Company Details
19.6.2.
Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6.
SWOT Analysis
19.6.7. Business Strategies
19.7.
Merck KGaA
19.7.1. Company Details
19.7.2. Company Overview
19.7.3.
Product Offerings
19.7.4. Key Developments
19.7.5.
Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8.
Shanghai Techwell
Biopharmaceutical Co., Ltd.
19.8.1.
Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5.
Financial Analysis
19.8.6. SWOT Analysis
19.8.7.
Business Strategies
19.9.
Vhb Life Sciences
Limited
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4.
Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10.
Walter Bushnell
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11.
Other Market Participants
20. Key Findings
Note: This ToC is tentative and can be changed according to the
research study conducted during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.